KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Source: NASDAQ.COM
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like HCAT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on HCAT
Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is 3.85 USD with a low forecast of 2.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.190
Low
2.75
Averages
3.85
High
5.00
Current: 2.190
Low
2.75
Averages
3.85
High
5.00
About HCAT
Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
- New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
- Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
- Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
- Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
Continue Reading
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
- New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
- Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
- Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
- Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
Continue Reading